We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.21 | -2.48971193416 | 48.6 | 50.42 | 44.71 | 726097 | 48.64081718 | CS |
4 | 9.77 | 25.9702286018 | 37.62 | 56.27 | 34.63 | 867245 | 46.81015395 | CS |
12 | 39.1 | 471.652593486 | 8.29 | 58.6936 | 7.79 | 1004288 | 44.20494706 | CS |
26 | 41.23 | 669.318181818 | 6.16 | 58.6936 | 5.65 | 527957 | 40.048126 | CS |
52 | 32.73 | 223.260572988 | 14.66 | 58.6936 | 5.65 | 319631 | 34.93972634 | CS |
156 | 13.39 | 39.3823529412 | 34 | 58.6936 | 5.65 | 186576 | 28.92315407 | CS |
260 | 13.39 | 39.3823529412 | 34 | 58.6936 | 5.65 | 186576 | 28.92315407 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions